Beyfortus® For Prevention of Respiratory Syncytial Virus (RSV) in Infants

• 2024

  Sign in to bookmark this resource.

  Sign in

---

Access Resources

• Job AidEN

About

This webpage provides a pharmacy update on the use of Beyfortus for the prevention of RSV in infants. The FDA approved nirsevimab for infants and an RSV vaccine for mothers last year. Real-world studies show nirsevimab is 80-90% effective in preventing RSV-related hospitalizations. Partners for Kids offers resources for nirsevimab administration. Nirsevimab is recommended for infants < 8 months and at-risk children 8-19 months. Dosing depends on weight and age. Nirsevimab is available through the VFC Program at no cost for eligible patients.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Niresivemab Library

Keywords: Infant; Pediatrics; Pharmacies; Pharmacy; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Respiratory Tract Infections; Immunization Programs; Antibodies, Monoclonal, Humanized

Institutions: Nationwide Children's Hospital

---

More like this

Job Aid: High Flow Nasal Cannula (HFNC) 2022 · Seattle Children's Hospital Bronchiolitis Clinical Practice Guideline 2022 · Mary Bridge Children’s Hospital News & Views: Nirsevimab Means Brushing Up on Passive Immunity Talking Points 2023 · Children's Hospital of Philadelphia

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---